nodes	percent_of_prediction	percent_of_DWPC	metapath
Escitalopram—SLC6A3—Gilles de la Tourette syndrome	0.91	1	CbGaD
Escitalopram—Citalopram—SLC6A3—Gilles de la Tourette syndrome	0.00773	1	CrCbGaD
Escitalopram—SLC6A2—autonomic nervous system—Gilles de la Tourette syndrome	0.00713	0.227	CbGeAlD
Escitalopram—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—Gilles de la Tourette syndrome	0.00187	0.0369	CbGpPWpGaD
Escitalopram—HTR2C—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.0015	0.0296	CbGpPWpGaD
Escitalopram—SLC6A4—Monoamine Transport—SLC6A3—Gilles de la Tourette syndrome	0.00143	0.0283	CbGpPWpGaD
Escitalopram—SLC6A3—midbrain—Gilles de la Tourette syndrome	0.00136	0.0432	CbGeAlD
Escitalopram—HTR2C—midbrain—Gilles de la Tourette syndrome	0.00132	0.0418	CbGeAlD
Escitalopram—SLC6A2—Amine compound SLC transporters—SLC6A3—Gilles de la Tourette syndrome	0.0013	0.0256	CbGpPWpGaD
Escitalopram—SLC6A4—midbrain—Gilles de la Tourette syndrome	0.00125	0.0396	CbGeAlD
Escitalopram—HTR2C—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00124	0.0244	CbGpPWpGaD
Escitalopram—SLC6A2—Monoamine Transport—SLC6A3—Gilles de la Tourette syndrome	0.00123	0.0243	CbGpPWpGaD
Escitalopram—SLC6A3—nervous system—Gilles de la Tourette syndrome	0.00112	0.0355	CbGeAlD
Escitalopram—HTR2C—nervous system—Gilles de la Tourette syndrome	0.00108	0.0343	CbGeAlD
Escitalopram—SLC6A3—central nervous system—Gilles de la Tourette syndrome	0.00108	0.0342	CbGeAlD
Escitalopram—HRH1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00107	0.0211	CbGpPWpGaD
Escitalopram—CHRM1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00107	0.021	CbGpPWpGaD
Escitalopram—HTR2C—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00105	0.0208	CbGpPWpGaD
Escitalopram—ADRA1A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00105	0.0207	CbGpPWpGaD
Escitalopram—HTR2C—central nervous system—Gilles de la Tourette syndrome	0.00104	0.0331	CbGeAlD
Escitalopram—SLC6A4—nervous system—Gilles de la Tourette syndrome	0.00102	0.0326	CbGeAlD
Escitalopram—HTR2C—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00102	0.0202	CbGpPWpGaD
Escitalopram—CHRM1—nervous system—Gilles de la Tourette syndrome	0.00102	0.0324	CbGeAlD
Escitalopram—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2A—Gilles de la Tourette syndrome	0.000996	0.0196	CbGpPWpGaD
Escitalopram—SLC6A4—central nervous system—Gilles de la Tourette syndrome	0.000987	0.0313	CbGeAlD
Escitalopram—CHRM1—central nervous system—Gilles de la Tourette syndrome	0.000983	0.0312	CbGeAlD
Escitalopram—HTR2C—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000953	0.0188	CbGpPWpGaD
Escitalopram—HRH1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000913	0.018	CbGpPWpGaD
Escitalopram—CHRM1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00091	0.0179	CbGpPWpGaD
Escitalopram—SLC6A2—nervous system—Gilles de la Tourette syndrome	0.000902	0.0287	CbGeAlD
Escitalopram—ADRA1A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000896	0.0177	CbGpPWpGaD
Escitalopram—HRH1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000886	0.0175	CbGpPWpGaD
Escitalopram—HTR2C—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000886	0.0175	CbGpPWpGaD
Escitalopram—CHRM1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000884	0.0174	CbGpPWpGaD
Escitalopram—ADRA1A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00087	0.0171	CbGpPWpGaD
Escitalopram—SLC6A2—central nervous system—Gilles de la Tourette syndrome	0.000869	0.0276	CbGeAlD
Escitalopram—HTR2C—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00086	0.017	CbGpPWpGaD
Escitalopram—SLC6A3—brain—Gilles de la Tourette syndrome	0.000855	0.0272	CbGeAlD
Escitalopram—ADRA1A—nervous system—Gilles de la Tourette syndrome	0.000839	0.0266	CbGeAlD
Escitalopram—HTR2C—brain—Gilles de la Tourette syndrome	0.000826	0.0262	CbGeAlD
Escitalopram—HRH1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000826	0.0163	CbGpPWpGaD
Escitalopram—CHRM1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000823	0.0162	CbGpPWpGaD
Escitalopram—ADRA1A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00081	0.016	CbGpPWpGaD
Escitalopram—ADRA1A—central nervous system—Gilles de la Tourette syndrome	0.000808	0.0257	CbGeAlD
Escitalopram—HTR2C—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000801	0.0158	CbGpPWpGaD
Escitalopram—SLC6A4—brain—Gilles de la Tourette syndrome	0.000783	0.0249	CbGeAlD
Escitalopram—CHRM1—brain—Gilles de la Tourette syndrome	0.00078	0.0248	CbGeAlD
Escitalopram—HRH1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000767	0.0151	CbGpPWpGaD
Escitalopram—CHRM1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000765	0.0151	CbGpPWpGaD
Escitalopram—ADRA1A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000753	0.0148	CbGpPWpGaD
Escitalopram—HRH1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000745	0.0147	CbGpPWpGaD
Escitalopram—CHRM1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000743	0.0146	CbGpPWpGaD
Escitalopram—ADRA1A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000731	0.0144	CbGpPWpGaD
Escitalopram—HRH1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000694	0.0137	CbGpPWpGaD
Escitalopram—CHRM1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000692	0.0136	CbGpPWpGaD
Escitalopram—SLC6A2—brain—Gilles de la Tourette syndrome	0.00069	0.0219	CbGeAlD
Escitalopram—ADRA1A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000681	0.0134	CbGpPWpGaD
Escitalopram—HTR2C—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000667	0.0132	CbGpPWpGaD
Escitalopram—HRH1—nervous system—Gilles de la Tourette syndrome	0.000649	0.0206	CbGeAlD
Escitalopram—ADRA1A—brain—Gilles de la Tourette syndrome	0.000641	0.0204	CbGeAlD
Escitalopram—HRH1—central nervous system—Gilles de la Tourette syndrome	0.000625	0.0199	CbGeAlD
Escitalopram—HRH1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000578	0.0114	CbGpPWpGaD
Escitalopram—CHRM1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000576	0.0114	CbGpPWpGaD
Escitalopram—ADRA1A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000567	0.0112	CbGpPWpGaD
Escitalopram—HTR2C—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000561	0.0111	CbGpPWpGaD
Escitalopram—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.000508	0.01	CbGpPWpGaD
Escitalopram—CYP3A4—nervous system—Gilles de la Tourette syndrome	0.000502	0.0159	CbGeAlD
Escitalopram—HRH1—brain—Gilles de la Tourette syndrome	0.000496	0.0158	CbGeAlD
Escitalopram—CYP2D6—nervous system—Gilles de la Tourette syndrome	0.000494	0.0157	CbGeAlD
Escitalopram—HRH1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000486	0.00959	CbGpPWpGaD
Escitalopram—CHRM1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000485	0.00955	CbGpPWpGaD
Escitalopram—CYP3A4—central nervous system—Gilles de la Tourette syndrome	0.000483	0.0154	CbGeAlD
Escitalopram—ADRA1A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000477	0.00941	CbGpPWpGaD
Escitalopram—CYP2D6—central nervous system—Gilles de la Tourette syndrome	0.000476	0.0151	CbGeAlD
Escitalopram—SLC6A4—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000426	0.00839	CbGpPWpGaD
Escitalopram—CYP2D6—brain—Gilles de la Tourette syndrome	0.000378	0.012	CbGeAlD
Escitalopram—SLC6A2—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000366	0.00722	CbGpPWpGaD
Escitalopram—SLC6A4—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.000358	0.00706	CbGpPWpGaD
Escitalopram—SLC6A4—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.000348	0.00686	CbGpPWpGaD
Escitalopram—SLC6A4—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.000324	0.00639	CbGpPWpGaD
Escitalopram—SLC6A4—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.000278	0.00548	CbGpPWpGaD
Escitalopram—SLC6A2—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.000231	0.00455	CbGpPWpGaD
Escitalopram—CHRM1—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.000214	0.00423	CbGpPWpGaD
Escitalopram—CHRM1—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.000208	0.00411	CbGpPWpGaD
Escitalopram—HTR2C—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000203	0.00401	CbGpPWpGaD
Escitalopram—HTR2C—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000197	0.00389	CbGpPWpGaD
Escitalopram—CHRM1—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.000194	0.00382	CbGpPWpGaD
Escitalopram—HTR2C—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000184	0.00363	CbGpPWpGaD
Escitalopram—HRH1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000176	0.00347	CbGpPWpGaD
Escitalopram—CHRM1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000176	0.00346	CbGpPWpGaD
Escitalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000174	0.00344	CbGpPWpGaD
Escitalopram—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000173	0.00341	CbGpPWpGaD
Escitalopram—HRH1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000171	0.00337	CbGpPWpGaD
Escitalopram—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000171	0.00336	CbGpPWpGaD
Escitalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000169	0.00333	CbGpPWpGaD
Escitalopram—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000168	0.00331	CbGpPWpGaD
Escitalopram—HTR2C—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000167	0.00329	CbGpPWpGaD
Escitalopram—HRH1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000159	0.00314	CbGpPWpGaD
Escitalopram—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000159	0.00313	CbGpPWpGaD
Escitalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000158	0.00311	CbGpPWpGaD
Escitalopram—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000156	0.00308	CbGpPWpGaD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000151	0.00298	CbGpPWpGaD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00015	0.00297	CbGpPWpGaD
Escitalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000149	0.00294	CbGpPWpGaD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000148	0.00292	CbGpPWpGaD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000147	0.00289	CbGpPWpGaD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000146	0.00288	CbGpPWpGaD
Escitalopram—HRH1—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000144	0.00285	CbGpPWpGaD
Escitalopram—CHRM1—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000144	0.00284	CbGpPWpGaD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000144	0.00284	CbGpPWpGaD
Escitalopram—ADRA1A—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000142	0.00279	CbGpPWpGaD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000137	0.00269	CbGpPWpGaD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000136	0.00268	CbGpPWpGaD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000134	0.00264	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000133	0.00262	CbGpPWpGaD
Escitalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000129	0.00255	CbGpPWpGaD
Escitalopram—HTR2C—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000129	0.00254	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000129	0.00254	CbGpPWpGaD
Escitalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000129	0.00254	CbGpPWpGaD
Escitalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000127	0.0025	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00012	0.00237	CbGpPWpGaD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000117	0.00231	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000115	0.00227	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000115	0.00226	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000113	0.00222	CbGpPWpGaD
Escitalopram—HRH1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000112	0.0022	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000112	0.0022	CbGpPWpGaD
Escitalopram—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000111	0.00219	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000111	0.00219	CbGpPWpGaD
Escitalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00011	0.00218	CbGpPWpGaD
Escitalopram—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00011	0.00216	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00011	0.00216	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000104	0.00205	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000104	0.00204	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000102	0.00201	CbGpPWpGaD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	9.56e-05	0.00189	CbGpPWpGaD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	9.53e-05	0.00188	CbGpPWpGaD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	9.38e-05	0.00185	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	8.4e-05	0.00166	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	7.5e-05	0.00148	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	7.28e-05	0.00144	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	7.28e-05	0.00144	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	7.26e-05	0.00143	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	7.15e-05	0.00141	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—HDC—Gilles de la Tourette syndrome	7.12e-05	0.0014	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	6.81e-05	0.00134	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	6.78e-05	0.00134	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	6.61e-05	0.0013	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—HDC—Gilles de la Tourette syndrome	6.55e-05	0.00129	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	6.5e-05	0.00128	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	6.48e-05	0.00128	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	6.37e-05	0.00126	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	6.31e-05	0.00124	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	6.29e-05	0.00124	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	6.19e-05	0.00122	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	6.16e-05	0.00121	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	5.9e-05	0.00116	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	5.88e-05	0.00116	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	5.88e-05	0.00116	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	5.86e-05	0.00115	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	5.79e-05	0.00114	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	5.77e-05	0.00114	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	5.73e-05	0.00113	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	5.71e-05	0.00113	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	5.62e-05	0.00111	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	5.34e-05	0.00105	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	5.32e-05	0.00105	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	5.24e-05	0.00103	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	4.75e-05	0.000936	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	4.31e-05	0.00085	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—HDC—Gilles de la Tourette syndrome	4.28e-05	0.000844	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	4.11e-05	0.000811	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	4.1e-05	0.000809	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	4.04e-05	0.000796	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.02e-05	0.000793	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.9e-05	0.00077	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.74e-05	0.000737	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.72e-05	0.000734	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.67e-05	0.000723	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.64e-05	0.000717	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.49e-05	0.000687	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.47e-05	0.000685	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.42e-05	0.000674	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.38e-05	0.000667	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.37e-05	0.000665	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.32e-05	0.000655	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.15e-05	0.000621	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.14e-05	0.000619	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.09e-05	0.00061	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.55e-05	0.000502	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.21e-05	0.000435	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.2e-05	0.000434	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.17e-05	0.000427	CbGpPWpGaD
